The role of catecholaminergic neurotransmission in attention and cognitio
Completed
- Conditions
- aandacht en leer problemen10037173
- Registration Number
- NL-OMON43560
- Lead Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
* Male
* No use of any psychopharmacological treatment at in the past or at time of inclusion.
* No presence of a physical/medical condition that may interfere with the study
* No contradiction for MRI
* Age between 18 and 30
* right handedness
Exclusion Criteria
* Diagnosis of a psychiatric disorder (DSM-V)
* Diagnosis of a neurological disorder
* Very high (>30) or low (>18) BMI
* Current recreational drug use/dependence (CIDI)
* Current alcohol dependence (CIDI)
* High blood pressure (>150 systolic, >100 diastolic)
* Non-responders to the mild stressor in session 1
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome is the difference in fMRI activity (measurement of brain<br /><br>blood flow) during the attention/memory task between placebo and atomoxetine<br /><br>session in relation to cortisol, alpha-amylase, blood pressure, heart rate and<br /><br>mood after the mild stressor</p><br>
- Secondary Outcome Measures
Name Time Method <p>Behavioural performance (reaction time, errors) on learning and attention tasks<br /><br>will be compared between placebo and atomoxetine session.</p><br>